Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.38 |
| ▸ | CNR1 | P21554 | 8/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251185 | 1.00 | CNR2 (0.38) | CNR2CNR1CYP19A1TDP1L3MBTL1 | |
| SCHEMBL18935500 | 1.00 | CNR2 (0.38) | CNR2CNR1CYP19A1TDP1L3MBTL1 | |
| SCHEMBL19251174 | 1.00 | CNR2 (0.38) | CNR2CNR1CYP19A1TDP1L3MBTL1 | |
| SCHEMBL18852713 | 0.98 | CNR2 (0.37) | CNR2CNR1CYP19A1TDP1L3MBTL1 | |
| SCHEMBL18721019 | 0.98 | CNR2 (0.37) | CNR2CNR1CYP19A1TDP1L3MBTL1 | |
| SCHEMBL22007446 | 0.98 | CYP19A1 (0.37) | CNR2CNR1CYP19A1TDP1L3MBTL1 | |
| SCHEMBL19251062 | 0.96 | CNR2 (0.36) | CNR2CNR1CYP19A1 | |
| SCHEMBL18909511 | 0.96 | CYP19A1 (0.36) | CNR2CNR1CYP19A1TDP1L3MBTL1 | |
| SCHEMBL19135597 | 0.93 | CYP19A1 (0.38) | CNR2CNR1CYP19A1 | |
| SCHEMBL18382253 | 0.92 | CYP19A1 (0.38) | CNR2CNR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210238176-A1 | PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-08-05 | — | — | US | disclosed |
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-13 | — | — | US | disclosed |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | PFIZER INC. | 2020-01-16 | — | — | US | disclosed |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-10183908-B2 | Compositions for the treatment of kidney and/or liver disease | VECTUS BIOSYSTEMS LIMITED (AU) | 2019-01-22 | — | — | US | disclosed |
| US-20180037539-A1 | COMPOSITIONS FOR THE TREATMENT OF KIDNEY AND/OR LIVER DISEASE | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-02-08 | — | — | US | disclosed |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183908-B2 | Compositions for the treatment of kidney and/or liver disease | FABP1, SLC10A1, GLS | CNR2 1291/4885CNR1 1305/4885CYP19A1 2988/4885 |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CNR2 1066/4885CNR1 1176/4885CYP19A1 526/4885 |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HDGF, HAVCR2 | CNR2 2890/4885CNR1 2120/4885CYP19A1 884/4885 |
| US-20180037539-A1 | COMPOSITIONS FOR THE TREATMENT OF KIDNEY AND/OR LIVER DISEASE | FABP1, SLC10A1, GLS | CNR2 1291/4885CNR1 1305/4885CYP19A1 2988/4885 |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | CNR2 887/4885CNR1 585/4885CYP19A1 2077/4885 |
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | CNR2 4524/4885CNR1 4239/4885CYP19A1 293/4885 |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | CNR2 887/4885CNR1 585/4885CYP19A1 2077/4885 |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | CNR2 887/4885CNR1 585/4885CYP19A1 2077/4885 |
| US-20210238176-A1 | PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | DDT, ACHE, CYP1B1 | CNR2 2140/4885CNR1 1760/4885CYP19A1 25/4885 |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | CNR2 2890/4885CNR1 2120/4885CYP19A1 884/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | CNR2 2902/4885CNR1 2040/4885CYP19A1 867/4885 |
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | CNR2 3923/4885CNR1 3702/4885CYP19A1 4810/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | CNR2 2902/4885CNR1 2040/4885CYP19A1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.